Drug intelligence / Profile preview

Verasone

Development stage: Phase 1
Lead developer: Diceros Therapeutics
Modality: Small Molecules
Administration: Intranasal, Irrigation

Overview

**Verasone** is Diceros Therapeutics' investigational, proprietary fixed-dose aqueous suspension of **verapamil + mometasone** for high-volume sinonasal irrigation in chronic rhinosinusitis. Mometasone is a glucocorticoid receptor agonist that suppresses sinonasal inflammation, while verapamil is an L-type calcium-channel blocker that also inhibits P-glycoprotein, with the intended effect of improving intracellular retention and anti-inflammatory activity of mometasone in sinonasal epithelial tissue. The product completed a Phase 1 single- and multiple-ascending-dose study in healthy participants.

Other names: Verasoneverapamil + mometasone

Targets

ABCB1 (P-glycoprotein)GR (Glucocorticoid receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Verasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verasone.

Explore the full profile